Objective    To evaluate the curative effect of potassium magnesium aspartate on arrhythmia and heart function in valve replacement postoperative patients of rheumatic heart disease.      Methods    Two hundred and eighty patients with rheumatic heart disease were divided into 2 groups in random

with no statistical significance. Treatment group (n=155) were received i.v. potassium magnesium aspartate 40 ml every day and control group (n=125) were only given conventional therapy. At the same time they were given same treatment. Blood magnesium level

blood potassium levels

arrhythmia incidences and heart function were also observed.     Results    Blood magnesium and potassium levels of the treatment group were higher than those of the control group (P0.05) in the 1st and 2nd days postoperatively. Stroke volume (SV)

cardiac output (CO) and ejection fraction (EF) of the treatment group were higher than those of the control group (P0.05). But there was no significant difference in the left ventricular end-systolic dimension (LVESD) between them. Cardiac arrhythmia incidence rate of the treatment group was fewer than that of control group after operation in 3 d after operation (P0.05). Premature ventricualr contraction

atrial fibrillation and paroxysmal supraventricular tachycardia event of the treatment group was fewer than those of control group (P0.05). There was no significant difference in the ventricular tachycardia

ventricle fibrillation and auricular flutter event between the 2 groups.      Conclusion    Potassium-magnesium aspartate is effective and safe to reduce premature ventricualr contraction

atrial fibrillation and paroxysmal supraventricular tachycardia event and to improve heart function for valve replacement postoperative patients of rheumatic heart disease.